trial

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

NCTId NCT05325645
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 450 (estimated)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2026-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
450 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-07-21
Primary completion
2026-02
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Investigators

1
Takeshi TsunodaStudy Director

Sites

1 total
Kure-shi, Japan

Linked catalysts

1
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schiz — primary completion2026-02

Facts & assertions

4 sourced
Enrollment
450
Phase
PHASE3
Primary Completion Date
2026-02
Status
RECRUITING
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Acute Schizophrenia
indication
investigator
Takeshi Tsunoda
person